In Vitro Profiling Drug Activity, Selectivity and Liability

Concepts for In Vitro Profiling Drug Activity, Selectivity and Liability 

MICHAEL B. BOLGER , ROBERT FRACZKIEWICZ , MICHAEL ENTZEROTH AND BOYD STEERE  

However, it is recognized that, despite all these efforts, the approval of new chemical entities (NCEs) has stagnated and reached an historical low in 2002 with 17 new molecule entities approved by the US Food and Drug Administration (US FDA) the approval rates only increased marginally the following year as 21 new entities were 

---